Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 30, 2026

A Next-generation Tissue Microarray (ngTMA) Protocol for Biomarker Studies
09:32

A Next-generation Tissue Microarray (ngTMA) Protocol for Biomarker Studies

Published on: September 23, 2014

Tissue microarray studies in bladder cancer.

Arndt Hartmann1

  • 1Institute of Pathology, University of Erlangen, Krankenhausstrasse 12, Erlangen, Germany. arndt.hartmann@uk-erlangen.de

Scandinavian Journal of Urology and Nephrology. Supplementum
|December 5, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Generation and characterization of hepatocellular carcinoma cell lines with enhanced cancer stem cell potential.

Journal of cellular and molecular medicine·2018
Same author

Fatal Encephalitis Associated with Borna Disease Virus 1.

The New England journal of medicine·2018
Same author

Addition of triple negativity of breast cancer as an indicator for germline mutations in predisposing genes increases sensitivity of clinical selection criteria.

BMC cancer·2018
Same author

CDKN2A as transcriptomic marker for muscle-invasive bladder cancer risk stratification and therapy decision-making.

Scientific reports·2018
Same author

Long noncoding RNA HOTAIR is upregulated in an aggressive subgroup of gastrointestinal stromal tumors (GIST) and mediates the establishment of gene-specific DNA methylation patterns.

Genes, chromosomes & cancer·2018
Same author

Asymmetric Omphalopagus in a Triplet after In Vitro Fertilization: A Rare Case of Conjoined Twinning.

Case reports in pediatrics·2018
Same journal

Bladder cancer-from pathogenesis to prevention, 2008. Proceedings of an international consultation organized by the WHO Collaborating Center for Urologic Tumors. April 24-25, 2008. Stockholm, Sweden.

Scandinavian journal of urology and nephrology. Supplementum·2009
Same journal

The global burden of urinary bladder cancer.

Scandinavian journal of urology and nephrology. Supplementum·2008
Same journal

Bladder cancer: chemoprevention, complementary approaches and budgetary considerations.

Scandinavian journal of urology and nephrology. Supplementum·2008
Same journal

Screening for bladder cancer: theoretical and practical issues in considering the treated and untreated natural history of the various forms of the disease.

Scandinavian journal of urology and nephrology. Supplementum·2008
Same journal

Combining a molecular profile with a clinical and pathological profile: biostatistical considerations.

Scandinavian journal of urology and nephrology. Supplementum·2008
Same journal

How to combine the molecular profile with the clinicopathological profile of urothelial neoplastic lesions.

Scandinavian journal of urology and nephrology. Supplementum·2008
See all related articles

Tissue microarray (TMA) technology enables high-throughput genomic and proteomic analysis of numerous small tissue samples. This method is crucial for bladder cancer research, linking molecular markers to patient outcomes and advancing clinical practice.

Area of Science:

  • Oncology
  • Genomics
  • Proteomics

Background:

  • Tissue microarray (TMA) methodology, established a decade ago, facilitates high-throughput genomic and proteomic analyses.
  • TMAs allow investigation of hundreds of minute tissue samples on a single slide, with small areas proven representative of the entire tumor block.
  • This technique provides reliable data on molecular markers and their correlation with patient clinical outcomes.

Purpose of the Study:

  • To review the applications and significance of tissue microarray (TMA) technology in bladder cancer research.
  • To highlight the utility of TMAs in evaluating prognostic markers, oncogene amplification, and signal transduction pathways.
  • To emphasize the role of TMAs in validating gene expression studies and translating molecular findings into clinical practice.

Main Methods:

More Related Videos

3-D Cell Culture System for Studying Invasion and Evaluating Therapeutics in Bladder Cancer
09:24

3-D Cell Culture System for Studying Invasion and Evaluating Therapeutics in Bladder Cancer

Published on: September 13, 2018

Related Experiment Videos

Last Updated: Jun 30, 2026

A Next-generation Tissue Microarray (ngTMA) Protocol for Biomarker Studies
09:32

A Next-generation Tissue Microarray (ngTMA) Protocol for Biomarker Studies

Published on: September 23, 2014

3-D Cell Culture System for Studying Invasion and Evaluating Therapeutics in Bladder Cancer
09:24

3-D Cell Culture System for Studying Invasion and Evaluating Therapeutics in Bladder Cancer

Published on: September 13, 2018

  • Utilizing tissue microarray (TMA) methodology for high-throughput analysis of numerous small tissue samples.
  • Applying TMAs to diverse bladder cancer research contexts, including clinical case series, stage-specific series, and therapy trials.
  • Employing TMAs for immunohistochemical evaluation, oncogene amplification frequency analysis, and multimarker expression studies.

Main Results:

  • TMAs have been extensively used in bladder cancer research to assess immunohistochemical markers for prognosis.
  • The technique aids in identifying amplification frequencies of candidate oncogenes and analyzing copy number alterations.
  • Multimarker expression studies and validation of gene expression data at the protein level are effectively performed using TMAs.

Conclusions:

  • Tissue microarray (TMA) technology is a valuable tool for high-throughput genomic and proteomic analyses in bladder cancer.
  • TMAs provide reliable data linking molecular markers to clinical outcomes, aiding in prognostic marker evaluation.
  • TMA technology is crucial for translating molecular discoveries in bladder cancer into clinical applications.